- Home
- PLUG vs SNDX Comparison
PLUG vs SNDX Comparison
Compare PLUG & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLUG
- SNDX
- Stock Information
- Founded
- PLUG 1997
- SNDX 2005
- Country
- PLUG United States
- SNDX United States
- Employees
- PLUG N/A
- SNDX N/A
- Industry
- PLUG Industrial Machinery/Components
- SNDX Biotechnology: Pharmaceutical Preparations
- Sector
- PLUG Energy
- SNDX Health Care
- Exchange
- PLUG Nasdaq
- SNDX Nasdaq
- Market Cap
- PLUG 1.8B
- SNDX 1.6B
- IPO Year
- PLUG 1999
- SNDX 2016
- Fundamental
- Price
- PLUG $1.87
- SNDX $15.83
- Analyst Decision
- PLUG Hold
- SNDX Strong Buy
- Analyst Count
- PLUG 21
- SNDX 11
- Target Price
- PLUG $4.51
- SNDX $36.00
- AVG Volume (30 Days)
- PLUG 61.3M
- SNDX 1.7M
- Earning Date
- PLUG 11-12-2024
- SNDX 11-05-2024
- Dividend Yield
- PLUG N/A
- SNDX N/A
- EPS Growth
- PLUG N/A
- SNDX N/A
- EPS
- PLUG N/A
- SNDX N/A
- Revenue
- PLUG $659,505,000.00
- SNDX $16,000,000.00
- Revenue This Year
- PLUG N/A
- SNDX N/A
- Revenue Next Year
- PLUG $43.82
- SNDX $219.92
- P/E Ratio
- PLUG N/A
- SNDX N/A
- Revenue Growth
- PLUG N/A
- SNDX N/A
- 52 Week Low
- PLUG $1.60
- SNDX $14.81
- 52 Week High
- PLUG $5.14
- SNDX $25.34
- Technical
- Relative Strength Index (RSI)
- PLUG 42.68
- SNDX 32.96
- Support Level
- PLUG $1.79
- SNDX $16.03
- Resistance Level
- PLUG $2.10
- SNDX $17.87
- Average True Range (ATR)
- PLUG 0.20
- SNDX 0.93
- MACD
- PLUG -0.03
- SNDX -0.45
- Stochastic Oscillator
- PLUG 9.64
- SNDX 1.26
About PLUG Plug Power Inc.
Plug Power is building an end-to-end green hydrogen ecosystem-from production, storage, and delivery to energy generation. The company plans to build and operate green hydrogen highways across North America and Europe. Plug will deliver its green hydrogen solutions directly to its customers and through joint venture partners into multiple end markets, including material handling, e-mobility, power generation, and industrial applications.
About SNDX Syndax Pharmaceuticals Inc.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The company's product candidates are entinostat which has direct effects on both cancer cells and immune regulatory cells, SNDX-6352 and SNDX-6352, an anti-CSF-1R monoclonal antibody, to enhance the body's immune response on tumors that have shown sensitivity to immunotherapy. Business activity of the group is primarily functioned through the region of United States.